ReviewCNS neuroscience & therapeutics2026
Neural Circuit Mechanisms of Disorders of Consciousness and Potential Therapeutic Targets of Brain Stimulation.
Review in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundDisorders of consciousness (DoC) lack an integrated framework to guide neuromodulation. This review updates three hierarchical frameworks-ARAS, mesocircuit, and ICNs-and maps therapeutic targets within each.
methodsWe synthesized recent neuroanatomical, optogenetic, neuroimaging, and clinical trial evidence, reevaluating classic frameworks and proposing a hierarchical integration to inform multi-target strategies.
resultsThree major updates are identified. In ARAS, glutamatergic neurons in PPN/LDT and parabrachial nucleus, rather than cholinergic neurons, are the primary arousal drivers; clinical translation relies on peripheral nerve stimulations with variable efficacy. The mesocircuit is expanded from a unidirectional GPi-mediated pathway to a bidirectional GPi-GPe balance modulated by dopamine and adenosine; DBS targeting CM-Pf/CL shows ~44.7% response rate (38/85) but lacks RCTs, whereas amantadine remains the sole Level 1 evidence. Within ICNs, the executive control network has the strongest RCT support, though efficacy depends on etiology and consciousness level; salience network stimulation is untested. These frameworks are hierarchically integrated: ARAS sustains wakefulness, mesocircuit enables cortical activation, and ICNs support conscious content.
conclusionFuture strategies should adopt multi-target, multi-level approaches grounded in individualized network profiling. Priorities include large-scale RCTs for DBS and stratified protocols based on etiology and consciousness level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.